Amanita Muscaria Fruiting Body American Ginseng Ch
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Amanita Muscaria Fruiting Body American Ginseng Ch
- Nine-Ingredient Botanical Compound (Yohimbine / Saw Palmetto / American Ginseng et al.): No Approved Indication — TxGNN Repurposing Assessment Not Feasible
Nine-Ingredient Botanical Compound (Yohimbine / Saw Palmetto / American Ginseng et al.): No Approved Indication — TxGNN Repurposing Assessment Not Feasible
One-Sentence Summary
This candidate is a complex mixture of nine botanical and mineral ingredients — including yohimbine, saw palmetto, American ginseng, damiana (Turnera diffusa), skullcap (Scutellaria lateriflora), chaste tree, Amanita muscaria, selenium, and phosphoric acid — with no regulatory approval in any jurisdiction on record. The TxGNN model was unable to generate any repurposing predictions for this combination, most likely because multi-ingredient botanical blends of this type are not represented as unified entities in the knowledge graph. As a result, no evidence level can be assigned and no repurposing direction is currently assessable.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory approval on record) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assessable (no prediction generated) |
| US/TW Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why Assessment Is Not Feasible
This submission contains nine distinct active substances bundled into a single compound entry:
| Ingredient | Known Pharmacological Role |
|---|---|
| Yohimbine | α₂-adrenergic antagonist; traditionally used for sexual dysfunction |
| Saw palmetto (Serenoa repens) | 5α-reductase inhibitory properties; BPH/androgenic conditions |
| American ginseng | Adaptogen; immune modulation |
| Chaste tree (Vitex agnus-castus) | Dopaminergic / prolactin-modulating herb |
| Damiana (Turnera diffusa leafy twig) | Traditional aphrodisiac; anxiolytic |
| Skullcap (Scutellaria lateriflora whole) | GABAergic / anxiolytic herb |
| Amanita muscaria fruiting body | Muscarinic receptor modulator; psychoactive at higher doses |
| Selenium | Essential trace mineral; antioxidant cofactor |
| Phosphoric acid | Acidifying excipient / stabiliser |
The TxGNN knowledge graph is built around single-molecule DrugBank entities. A nine-ingredient botanical blend cannot be mapped to a single DrugBank ID, so the prediction pipeline has no entry point. This is a structural data limitation, not a clinical judgement about the ingredients themselves.
Individually, several ingredients (especially yohimbine and saw palmetto) do have DrugBank records and published clinical evidence. A meaningful repurposing analysis would require decomposing this compound into individual components and running TxGNN on each separately.
US/TW Market Information
No regulatory authorisations are on record for this exact combination in Taiwan or the United States.
Safety Considerations
Several ingredients in this mixture carry clinically significant safety signals that must be addressed before any further evaluation:
- Yohimbine: Narrow therapeutic index; documented risks of hypertensive crisis, tachycardia, anxiety, and interactions with MAOIs and antihypertensives.
- Amanita muscaria: Contains ibotenic acid and muscimol; toxic and psychoactive at non-micro doses; regulatory status varies by jurisdiction.
- Phosphoric acid: Corrosive excipient; safe only within tightly controlled pH ranges.
Formal safety data (package insert warnings, contraindications, DDI profile) are not available for this combination. Please consult primary literature for each individual ingredient before proceeding.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline cannot process a nine-ingredient botanical mixture as a unified entity, and no original indication, regulatory approval, or repurposing prediction exists to evaluate. The presence of Amanita muscaria and yohimbine also raises independent safety concerns that require resolution before any development pathway is considered.
To proceed, the following is needed:
- Decompose into individual components: Run TxGNN repurposing analysis separately for each of the nine ingredients using their individual DrugBank IDs (where available — yohimbine: DB01392; saw palmetto: DB12880; selenium: DB01593; American ginseng: DB15699).
- Clarify the intended indication: Identify the clinical rationale for combining these nine ingredients — the profile (yohimbine + saw palmetto + damiana) strongly suggests a sexual health / andrological target, but this must be confirmed by the submitter.
- Amanita muscaria safety review: Determine the dose level and extract type; this ingredient requires a standalone regulatory and toxicological assessment before any human use pathway.
- DDI assessment per component: Run individual DDI queries for yohimbine (especially MAOIs, antihypertensives, stimulants) and ginseng (especially anticoagulants).
- Regulatory feasibility check: Confirm whether this combination can be registered as a botanical drug (e.g., FDA Botanical Drug Guidance) or dietary supplement, and whether Amanita muscaria is permissible as an ingredient in the target market.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.